JP2019507158A - エソメプラゾールを含有する製剤 - Google Patents
エソメプラゾールを含有する製剤 Download PDFInfo
- Publication number
- JP2019507158A JP2019507158A JP2018545372A JP2018545372A JP2019507158A JP 2019507158 A JP2019507158 A JP 2019507158A JP 2018545372 A JP2018545372 A JP 2018545372A JP 2018545372 A JP2018545372 A JP 2018545372A JP 2019507158 A JP2019507158 A JP 2019507158A
- Authority
- JP
- Japan
- Prior art keywords
- drug
- compartment
- layer
- pellet
- esomeprazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
Claims (6)
- 不活性コア、不活性コア上にコーティングされた薬物層および腸溶層でコーティングされた最外層を含む第1区画ペレットと;不活性コア、不活性コア上にコーティングされた薬物層および腸溶層でコーティングされた最外層を含む第2区画ペレットと;を含有する複数の単位区画を含む製剤であって、
第1区画ペレットの薬物層は、活性成分としてのエソメプラゾールを含み、
第2区画ペレットの薬物層は、活性成分としてのエソメプラゾールおよび可溶化剤としてのメグルミンを含み、
第1区画ペレットは、溶出試験法第1法により毎分100回転で試験を行うとき、溶出開始後10分までに単位区画内の活性成分が全量に対して5%以下まで放出され、30分までに活性成分が全量に対して80%以上放出され、
第2区画ペレットは、溶出試験法第1法により毎分100回転で試験を行うとき、溶出開始後3時間までの単位区画内の活性成分が全量に対して5%以下まで放出され、5時間までに活性成分が全量に対して70%以上放出されることを特徴とする製剤。 - 第1区画ペレットが、薬物層と腸溶層でコーティングされた最外層との間に分離層をさらに含むことを特徴とする請求項1に記載の製剤。
- 第2の区画ペレットが、薬物層と腸溶層でコーティングされた最外層との間に分離層をさらに含み、分離層が徐放性高分子を含むことを特徴とする請求項1に記載の製剤。
- 第2区画ペレットの薬物層が、徐放性高分子をさらに含むことを特徴とする請求項1に記載の製剤。
- 第2区画ペレットの薬物層が、界面活性剤をさらに含むことを特徴とする請求項1に記載の製剤。
- 界面活性剤がポリソルベートであることを特徴とする請求項5に記載の製剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160024669A KR101884230B1 (ko) | 2016-02-29 | 2016-02-29 | 에소메프라졸을 포함하는 제제 |
KR10-2016-0024669 | 2016-02-29 | ||
PCT/KR2017/000550 WO2017150803A1 (ko) | 2016-02-29 | 2017-01-17 | 에소메프라졸을 포함하는 제제 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2019507158A true JP2019507158A (ja) | 2019-03-14 |
Family
ID=59744180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018545372A Ceased JP2019507158A (ja) | 2016-02-29 | 2017-01-17 | エソメプラゾールを含有する製剤 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20190046459A1 (ja) |
EP (1) | EP3424496A4 (ja) |
JP (1) | JP2019507158A (ja) |
KR (1) | KR101884230B1 (ja) |
CN (1) | CN108697648A (ja) |
AU (1) | AU2017226585A1 (ja) |
BR (1) | BR112018017214A2 (ja) |
CA (1) | CA3014864C (ja) |
MX (1) | MX2018010387A (ja) |
RU (1) | RU2018134035A (ja) |
WO (1) | WO2017150803A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111991367A (zh) * | 2020-09-21 | 2020-11-27 | 青岛吉达巴尔国际贸易有限公司 | 一种埃索美拉唑镁脉冲微丸胶囊剂及制备方法 |
KR20220091629A (ko) | 2020-12-23 | 2022-07-01 | (주)휴온스 | 안정성이 증가된 에스오메프라졸 함유 장용성 코팅 정제 및 이의 제조방법 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000056287A1 (fr) * | 1999-03-19 | 2000-09-28 | Kyowa Hakko Kogyo Co., Ltd. | Comprimes et leurs procedes de fabrication |
JP2001526213A (ja) * | 1997-12-22 | 2001-12-18 | アストラゼネカ・アクチエボラーグ | 経口医薬パルス放出剤形 |
JP2007504270A (ja) * | 2003-09-05 | 2007-03-01 | スパーナス ファーマシューティカル インコーポレイテッド | 溶解度増大による治療化合物の浸透性送達 |
JP2008519069A (ja) * | 2004-11-04 | 2008-06-05 | アストラゼネカ・アクチエボラーグ | プロトンポンプ阻害剤用の新規な改変された放出のペレット製剤 |
US20110293713A1 (en) * | 2010-06-01 | 2011-12-01 | Snehalatha Movva | Pharmaceutical formulations comprising nsaid and proton pump inhibitor drugs |
JP2012523427A (ja) * | 2009-04-09 | 2012-10-04 | アルカーメス ファーマ アイルランド リミテッド | 薬物送達組成物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8206741B2 (en) * | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
JP4933033B2 (ja) * | 2003-03-17 | 2012-05-16 | 武田薬品工業株式会社 | 放出制御組成物 |
AU2003272081A1 (en) * | 2003-09-25 | 2005-04-11 | Natco Pharma Limited | Enteric soft gelatin capsule containing esomeprazole and method of preparation |
CA2694602A1 (en) * | 2007-07-27 | 2009-02-05 | Depomed, Inc. | Pulsatile gastric retentive dosage forms |
US20090228941A1 (en) * | 2008-03-05 | 2009-09-10 | At&T Intellectual Property, Lp | Video System and a Method of Using the Video System |
EP2344139A1 (en) * | 2008-09-09 | 2011-07-20 | AstraZeneca AB | Method for delivering a pharmaceutical composition to patient in need thereof |
US20110177164A1 (en) * | 2008-10-06 | 2011-07-21 | Gopal Rajan | Pharmaceutical Compositions Comprising Amorphous Esomeprazole, Dosage Forms And Process Thereof |
KR102060738B1 (ko) * | 2012-12-13 | 2019-12-30 | 한미약품 주식회사 | 에스오메프라졸 유리염기 또는 그의 알칼리염을 포함하는 고미가 차폐된 약학 제제 및 이의 제조방법 |
CN105163743A (zh) * | 2013-02-13 | 2015-12-16 | 红山生物医药有限公司 | 用于治疗幽门螺杆菌的药物组合物 |
-
2016
- 2016-02-29 KR KR1020160024669A patent/KR101884230B1/ko active IP Right Grant
-
2017
- 2017-01-17 JP JP2018545372A patent/JP2019507158A/ja not_active Ceased
- 2017-01-17 CA CA3014864A patent/CA3014864C/en not_active Expired - Fee Related
- 2017-01-17 US US16/080,248 patent/US20190046459A1/en not_active Abandoned
- 2017-01-17 BR BR112018017214A patent/BR112018017214A2/pt not_active Application Discontinuation
- 2017-01-17 AU AU2017226585A patent/AU2017226585A1/en not_active Abandoned
- 2017-01-17 MX MX2018010387A patent/MX2018010387A/es unknown
- 2017-01-17 CN CN201780013697.8A patent/CN108697648A/zh active Pending
- 2017-01-17 WO PCT/KR2017/000550 patent/WO2017150803A1/ko active Application Filing
- 2017-01-17 EP EP17760207.5A patent/EP3424496A4/en not_active Withdrawn
- 2017-01-17 RU RU2018134035A patent/RU2018134035A/ru not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001526213A (ja) * | 1997-12-22 | 2001-12-18 | アストラゼネカ・アクチエボラーグ | 経口医薬パルス放出剤形 |
WO2000056287A1 (fr) * | 1999-03-19 | 2000-09-28 | Kyowa Hakko Kogyo Co., Ltd. | Comprimes et leurs procedes de fabrication |
JP2007504270A (ja) * | 2003-09-05 | 2007-03-01 | スパーナス ファーマシューティカル インコーポレイテッド | 溶解度増大による治療化合物の浸透性送達 |
JP2008519069A (ja) * | 2004-11-04 | 2008-06-05 | アストラゼネカ・アクチエボラーグ | プロトンポンプ阻害剤用の新規な改変された放出のペレット製剤 |
JP2012523427A (ja) * | 2009-04-09 | 2012-10-04 | アルカーメス ファーマ アイルランド リミテッド | 薬物送達組成物 |
US20110293713A1 (en) * | 2010-06-01 | 2011-12-01 | Snehalatha Movva | Pharmaceutical formulations comprising nsaid and proton pump inhibitor drugs |
Non-Patent Citations (1)
Title |
---|
INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACEUTICAL SCIENCES, vol. 4, no. 3, JPN6020028393, 2013, pages 328 - 335, ISSN: 0004319477 * |
Also Published As
Publication number | Publication date |
---|---|
MX2018010387A (es) | 2018-11-29 |
BR112018017214A2 (pt) | 2019-01-02 |
EP3424496A1 (en) | 2019-01-09 |
EP3424496A4 (en) | 2020-01-15 |
CA3014864A1 (en) | 2017-09-08 |
CA3014864C (en) | 2021-01-12 |
KR101884230B1 (ko) | 2018-08-01 |
US20190046459A1 (en) | 2019-02-14 |
RU2018134035A3 (ja) | 2020-04-23 |
RU2018134035A (ru) | 2020-04-01 |
AU2017226585A1 (en) | 2018-10-04 |
KR20170101721A (ko) | 2017-09-06 |
WO2017150803A1 (ko) | 2017-09-08 |
CN108697648A (zh) | 2018-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3902228B2 (ja) | 結腸デリバリー用の医薬投与形態 | |
JP5253381B2 (ja) | シグモイド放出プロファイルを有するオキサカルバゼピンの制御放出製剤 | |
JPWO2005092336A1 (ja) | 溶出制御製剤とその製造方法 | |
EP2958579A1 (en) | Oral steroid formulations for use in the treatment of intestinal fibrosis | |
CN103458880A (zh) | 口服给药的单位剂型 | |
JP5479909B2 (ja) | 新規製剤 | |
RU2744576C2 (ru) | Пероральные фармацевтические композиции месалазина | |
AU2021107174A4 (en) | Vitamin d pediatric dosage forms, methods of making and using | |
TW201206501A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
CN110087632A (zh) | 乳酸钙组合物和使用方法 | |
US20130243861A1 (en) | Press-coated tablets of prednisone | |
JPWO2007037259A1 (ja) | 生体内での崩壊性を向上させたパルス製剤 | |
JP5685641B2 (ja) | フェノフィブリン酸及びアルカリ化剤を含む経口用医薬組成物 | |
RU2484816C2 (ru) | Фармацевтические композиции реина или диацереина | |
JP2019507158A (ja) | エソメプラゾールを含有する製剤 | |
JP2018508501A (ja) | タムスロシン塩酸塩含有徐放性顆粒を含む経口用薬剤学的製剤 | |
WO2004096208A9 (en) | Composition for oral administration containing alkylene dioxybenzene derivative | |
KR20220015437A (ko) | 피리미디닐아미노-피라졸 화합물의 변형 방출 제제, 및 치료 방법 | |
TWI568455B (zh) | 每日一次投藥之提供藥學及臨床效果之莫沙必利持續釋放製劑 | |
EA043575B1 (ru) | Фармацевтическая композиция для перорального приема с контролируемой скоростью растворения, содержащая пеллеты с замедленным высвобождением, содержащие тамсулозина гидрохлорид |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190905 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20200415 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200717 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200804 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201028 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210316 |
|
A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20210727 |